MX377276B - Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda). - Google Patents
Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda).Info
- Publication number
- MX377276B MX377276B MX2016005567A MX2016005567A MX377276B MX 377276 B MX377276 B MX 377276B MX 2016005567 A MX2016005567 A MX 2016005567A MX 2016005567 A MX2016005567 A MX 2016005567A MX 377276 B MX377276 B MX 377276B
- Authority
- MX
- Mexico
- Prior art keywords
- ethanamine
- pyridin
- phenyl
- nmda
- prodrugs
- Prior art date
Links
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899903P | 2013-11-05 | 2013-11-05 | |
| PCT/GB2014/053236 WO2015067923A1 (en) | 2013-11-05 | 2014-10-30 | Nmda antagonist prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005567A MX2016005567A (es) | 2016-07-21 |
| MX377276B true MX377276B (es) | 2025-03-07 |
Family
ID=51947383
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005567A MX377276B (es) | 2013-11-05 | 2014-10-30 | Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda). |
| MX2020011946A MX394633B (es) | 2013-11-05 | 2014-10-30 | Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011946A MX394633B (es) | 2013-11-05 | 2014-10-30 | Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda) |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9822075B2 (OSRAM) |
| EP (3) | EP3564234B1 (OSRAM) |
| JP (4) | JP6479834B2 (OSRAM) |
| KR (2) | KR102336426B1 (OSRAM) |
| CN (2) | CN111187202B (OSRAM) |
| AR (1) | AR098319A1 (OSRAM) |
| AU (1) | AU2014345407B2 (OSRAM) |
| CA (1) | CA2928004C (OSRAM) |
| CY (1) | CY1121749T1 (OSRAM) |
| DK (1) | DK3066091T3 (OSRAM) |
| ES (3) | ES2894903T3 (OSRAM) |
| HR (2) | HRP20241784T1 (OSRAM) |
| HU (2) | HUE045001T2 (OSRAM) |
| LT (1) | LT3066091T (OSRAM) |
| MX (2) | MX377276B (OSRAM) |
| PL (2) | PL4001272T3 (OSRAM) |
| PT (1) | PT3066091T (OSRAM) |
| RS (2) | RS66369B1 (OSRAM) |
| RU (1) | RU2695372C2 (OSRAM) |
| SI (1) | SI3066091T1 (OSRAM) |
| SM (1) | SMT202500023T1 (OSRAM) |
| TR (1) | TR201909632T4 (OSRAM) |
| TW (1) | TW201609653A (OSRAM) |
| UY (1) | UY35823A (OSRAM) |
| WO (1) | WO2015067923A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2894903T3 (es) | 2013-11-05 | 2022-02-16 | Astrazeneca Ab | Profármacos antagonistas de NMDA |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| CN107578281B (zh) * | 2017-08-31 | 2021-03-30 | 湖南大学 | 电子商务环境下用户优惠券行为预测方法及模型构建方法 |
| KR20230026449A (ko) * | 2020-06-23 | 2023-02-24 | 바이오하벤 테라퓨틱스 리미티드 | (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형 |
| WO2025137661A1 (en) * | 2023-12-22 | 2025-06-26 | Biohaven Therapeutics Ltd. | Combination treatment of neurological disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7909514L (sv) * | 1979-11-16 | 1981-05-17 | Astra Laekemedel Ab | Nya halofenyl-pyridyl-allylaminderivat |
| US4769466A (en) * | 1987-02-06 | 1988-09-06 | Pennwalt Corporation | 2-aminoacetamide pyridinyl derivatives |
| EP0356035B1 (en) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
| KR100259567B1 (ko) * | 1992-04-03 | 2000-07-01 | 클래스 빌헬름슨 | 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머 |
| SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| US6613879B1 (en) * | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| US6407235B1 (en) | 2000-08-21 | 2002-06-18 | Hoffmann-La Roche Inc. | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
| EP1404324B2 (en) * | 2001-06-11 | 2011-04-06 | XenoPort, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| WO2005066122A2 (en) | 2003-12-30 | 2005-07-21 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| CA2621847A1 (en) * | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
| CN101246417B (zh) | 2007-02-13 | 2010-09-29 | 艾威梯科技(北京)有限公司 | 音频数据流输入/输出无间断软件切换的方法和系统 |
| CA2710538A1 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| EP2525830B1 (en) * | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| US8580850B2 (en) * | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
| ES2894903T3 (es) | 2013-11-05 | 2022-02-16 | Astrazeneca Ab | Profármacos antagonistas de NMDA |
-
2014
- 2014-10-30 ES ES19166031T patent/ES2894903T3/es active Active
- 2014-10-30 PL PL21196371.5T patent/PL4001272T3/pl unknown
- 2014-10-30 EP EP19166031.5A patent/EP3564234B1/en active Active
- 2014-10-30 SM SM20250023T patent/SMT202500023T1/it unknown
- 2014-10-30 EP EP21196371.5A patent/EP4001272B1/en active Active
- 2014-10-30 HR HRP20241784TT patent/HRP20241784T1/hr unknown
- 2014-10-30 CN CN202010014023.3A patent/CN111187202B/zh active Active
- 2014-10-30 TR TR2019/09632T patent/TR201909632T4/tr unknown
- 2014-10-30 HU HUE14802476A patent/HUE045001T2/hu unknown
- 2014-10-30 MX MX2016005567A patent/MX377276B/es active IP Right Grant
- 2014-10-30 AU AU2014345407A patent/AU2014345407B2/en active Active
- 2014-10-30 CN CN201480060416.0A patent/CN105683180B/zh active Active
- 2014-10-30 DK DK14802476.3T patent/DK3066091T3/da active
- 2014-10-30 PL PL14802476T patent/PL3066091T3/pl unknown
- 2014-10-30 MX MX2020011946A patent/MX394633B/es unknown
- 2014-10-30 SI SI201431242T patent/SI3066091T1/sl unknown
- 2014-10-30 HR HRP20191159TT patent/HRP20191159T1/hr unknown
- 2014-10-30 PT PT14802476T patent/PT3066091T/pt unknown
- 2014-10-30 EP EP14802476.3A patent/EP3066091B1/en active Active
- 2014-10-30 ES ES14802476T patent/ES2733344T3/es active Active
- 2014-10-30 RS RS20241459A patent/RS66369B1/sr unknown
- 2014-10-30 RU RU2016119493A patent/RU2695372C2/ru active
- 2014-10-30 JP JP2016551069A patent/JP6479834B2/ja active Active
- 2014-10-30 LT LTEP14802476.3T patent/LT3066091T/lt unknown
- 2014-10-30 WO PCT/GB2014/053236 patent/WO2015067923A1/en not_active Ceased
- 2014-10-30 HU HUE21196371A patent/HUE070532T2/hu unknown
- 2014-10-30 RS RS20190821A patent/RS58991B1/sr unknown
- 2014-10-30 CA CA2928004A patent/CA2928004C/en active Active
- 2014-10-30 US US15/034,727 patent/US9822075B2/en active Active
- 2014-10-30 KR KR1020167014625A patent/KR102336426B1/ko active Active
- 2014-10-30 ES ES21196371T patent/ES2999064T3/es active Active
- 2014-10-30 KR KR1020217039470A patent/KR102469167B1/ko active Active
- 2014-11-05 AR ARP140104166A patent/AR098319A1/es unknown
- 2014-11-05 TW TW103138423A patent/TW201609653A/zh unknown
- 2014-11-05 UY UY0001035823A patent/UY35823A/es not_active Application Discontinuation
-
2017
- 2017-10-17 US US15/785,654 patent/US10207994B2/en active Active
-
2019
- 2019-01-20 US US16/252,648 patent/US10815199B2/en active Active
- 2019-02-05 JP JP2019018440A patent/JP6633233B2/ja active Active
- 2019-07-02 CY CY20191100691T patent/CY1121749T1/el unknown
- 2019-12-10 JP JP2019222567A patent/JP6856737B2/ja active Active
-
2020
- 2020-10-26 US US17/079,553 patent/US20210040039A1/en active Pending
-
2021
- 2021-03-18 JP JP2021044193A patent/JP7234278B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| MY176285A (en) | Anti-fcrh5 antibodies | |
| MX375378B (es) | Formulaciones de anticuerpos anti-pdl1. | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| UY4167Q (es) | Par de auriculares | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| MX373309B (es) | Composiciones antibióticas de ceftolozano. | |
| MX391040B (es) | Formulacion de alta concentracion. | |
| CY1121749T1 (el) | Προφαρμακα ανταγωνιστων nmda | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| IN2013MU00848A (OSRAM) | ||
| EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| CL2015002358A1 (es) | Compuestos bicíclicos. | |
| CL2016001488A1 (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201591709A1 (ru) | 5-бром-индирубины | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |